Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

88 results
  1. ... Fowler B, Yue WW, Baumgartner MR. 3-methylcrotonyl-CoA carboxylase deficiency: clinical, biochemical, enzymatic and molecular studies in 88 individuals. ...
  2. ... Visser G. Fatty acid oxidation flux predicts the clinical severity of VLCAD ... and outcome of patients diagnosed through newborn screening in Victoria. ...
  3. ... Viau K, Botto LD, Pasquali M, Longo N. Clinical and biochemical outcomes of patients with medium-chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab. 2020;129:13- ...
  4. ... LD, Pasquali M, Longo N. Diagnosis, treatment, and clinical outcome of patients with mitochondrial trifunctional protein/long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency. JIMD Rep. 2017; 31 :63–71. [ ...
  5. ... of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes. J Inherit Metab Dis. 2019;42:414-23. [ ...
  6. ... more is considered clinically important Global Function Summary outcome assessment of overall severity of condition Any improvement in global function is considered clinical improvement; however, results depend on an individual physician’ ...
  7. ... 1200/jop.19.00772. PMID: 32427537. - Addresses ONLY clinical trial recruitment outcome [ PMC free article : PMC7489480 ] [ PubMed : 32427537 ] [ CrossRef ] Hianik RS, Owonikoko T, Switchenko J, et al. Evaluating the impact of the Patient Preference Assessment Tool on clinicians’ recommendations for phase I oncology ...
  8. ... 1200/JCO.2001.19.13.3163. PMID: 11432882. Outcome [ PubMed : 11432882 ] [ CrossRef ] 1347. Merz EL, Tomfohr-Madsen L. Sleep Disruption in Pediatric Cancer Survivors: Conceptual Framework and Opportunities for Clinical Assessment and Behavioral Treatment. Am J Lifestyle Med. 2018 ...
  9. ... sample may not be representative of a larger clinical population Quality assessment: Overall rating: Poor Comments: - Unblinded - Randomization protocol poorly described - Small sample size - Poor reporting of outcomes by drug Applicability: - Inadequate description of patient population - ...
  10. ... CH) (DACH) recommendations have been used in several clinical trials and have resulted in ... of glutaryl-CoA. Combined metabolic therapy includes the following [ Boy et ...
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · next · last